Libertad24 - Comercio de valores

Börse München, the finance and investment news platform of the Munich Stock Exchange, has published a market commentary by Dominik Mayr, Director of Freedom24 Germany on how the fast growing Longevity Trend is shaping new opportunities for investors. With rising interest from the Silicon Valley and PwC forecasting a market volume of more than €38 billion by 2030, Dominik explains why this development matters not only for biotechnology but also for long-term portfolio strategy. 📈 Dominik highlights that the longevity segment is among the fastest-growing biotechnology sectors and notes that most innovation happens at the intersection of cell technology, epigenetics, and artificial intelligence to significantly extend the healthy lifespan. While the industry is still in an early phase, he points out that "for investors, this means high return potential, but also a lengthy ‘package insert’ with risks due to clinical trials and regulatory developments." 🧬 Key companies discussed in the piece include Recursion Pharmaceuticals with its AI-driven drug-development platform, Geron Corporation with its approved cancer therapy Rytelo, and Voyager Therapeutics, which is working on treatments for neurodegenerative diseases. The analysis further considers Denali Therapeutics, PacBio, Anika Therapeutics, Ocugen, and ITeos Therapeutics, as well as funds and ETFs such as the SPDR Fund, the ARK Genomic Revolution ETF, and the iShares Nasdaq Biotechnology ETF. In conclusion, Dominik outlines how the Longevity Trend may translate into a long-term investment strategy: "We are currently witnessing the emergence of a new industry in which initial successes could generate a market capitalization of several billion euros. For conservative investors, it is advisable to hold 5 to 10 percent of their portfolio in ETFs and large pharmaceutical companies. For more aggressive investors, it is advisable to open selective positions in promising biotech companies." 🔗 Read more on Börse München